Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer

Oncology

Volumn 73, Issue 5-6, 2008, Pages 316-323

  Poettgen, Christoph ^a   Theegarten, Dirk ^a   Eberhardt, Wilfried ^a   Levegruen, Sabine ^a   Gauler, Thomas ^a   Krbek, Thomas ^b   Stamatis, Georgios ^b   Teschler, Helmut ^b   Kuehl, Hilmar ^a   Bockisch, Andreas ^a   Stuschke, Martin ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b RUHRLANDKLINIK   (Germany)

Author keywords

Chemoradiotherapy; Dual modality PET CT; Locally advanced non small cell lung cancer; Macrophage infiltration; Neoadjuvant

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE;

EID: 45549105088     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000134474     Document Type: Article

References (30)

1. Albain K, Rusch V, Crowley J, Rice T, Turrisi A, Weick J, Lonchyna V, Presant C, McKenna R, Gandara D, Fosmire H, Taylor S, Stelzer K, Beasley K, Livingston R: Long-term survival after concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer: 6-year outcomes from Southwest Oncology Group Study 8805. Proc Am Soc Clin Oncol 1999;18:467.
2. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Mueller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622-634.
3. Grunenwald DH, Andre F, Le Pechoux C, Girard P, Lamer C, Laplanche A, Tarayre M, Arriagada R, Le Chevalier T: Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:796-802.
4. Stamatis G, Eberhardt W, Stüben G, Bildat S, Dahler O, Hillejan L: Preoperative chemoradiotherapy and surgery for selected nonsmall cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg 1999;68:1144-1149.
5. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ: FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179-187.
6. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M: Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-2657.
7. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK: Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small lung cancer. Ann Thorac Surg 2004;77:254-259.
8. Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, Ginsberg RJ, Rusch VW, Larson SM: An initial experience with FDG-PET in the imaging of residual disease after induction chemotherapy for lung cancer. Ann Thorac Surg 2002;73:529-536.
9. Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR: Positron emission tomography scanning with 2-fluoro-2-deosy-D-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003;125:938-944.
10. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA: Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-1909.
11. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362-8370.
12. Schmücking M, Baum RP, Bonnet R, Junker K, Müller KM: Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment. Pathologe 2005;26:178-190.
13. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V: Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-3260.
14. Choi NC, Fischman AJ, Niemierko A, Ryu JS, Lynch T, Wain J, Wright C, Fidias P, Mathisen D: Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;54:1024-1035.
15. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA: 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776-1785.
16. 18F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer. Jpn J Clin Oncol 2005;35:271-273.
17. 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97-106.
18. Beyer T, Townsend D: Dual-modality PET/CT acquisition systems for clinical oncology; in Oehr P, Biersack HJ, Coleman E (eds): PET and PET/CT in Clinical Oncology. Heidelberg, Springer, 2003, pp 9-28.
19. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, Alavi A: Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nocules on FDG-PET. Eur J Nucl Med 2002;29:1639-1647.
20. Junker K, Langner K, Klinke F, Bosse U, Thomas M: Grading of tumour regression in non-small cell lung cancer: morphology and prognosis. Chest 2001;120:1584-1591.
21. Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181.
22. SAS Institute Inc.: SAS/STAT User's Guide, Version 6, ed 4. Cary, SAS Institute Inc., 1989.
23. 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 2001;42:1605-1613.
24. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL: Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-1292.
25. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK: FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005;63:1053-1059.
26. 18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002;4:301-310.
27. 18F]fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med 2003;30:267-273.
28. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T: Intratmoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-1980.
29. 18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682-688.
30. de Geus-Oei LF, van Krieken JHJM, Aliredjo RP, Krabbe PFM, Frielink C, Verhagen AFT, Boerman OC, Oyen WJG: Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79-87.